Compass Therapeutics reports strong Phase 2/3 results for tovecimig in biliary tract cancer and advances pipeline with new trials.

Compass Therapeutics announced positive Phase 2/3 trial results for tovecimig, showing significant improvement in progression-free survival and overall response rate for biliary tract cancer patients. The drug received Orphan Drug Designation and the company plans a BLA submission later this year. Additionally, Phase 1 studies for CTX-8371 and CTX-10726 bispecific antibodies are progressing, with data presentations expected in 2026. The company holds $195 million in cash, supporting operations into 2028.